Quantum Genesis AI Corp. has issued a statement regarding the Caveat Emptor designation placed on the company's securities by OTC Markets Group, Inc. on February 12, 2026. Since the designation was applied, the company has made several attempts to communicate with OTC Markets to better understand the basis for the designation and determine what steps may be necessary to address the matter. OTC Markets has indicated that the designation relates to a public interest concern, prompting the company to request additional clarification while intending to continue cooperating with OTC Markets.
OTC Markets recently informed Quantum Genesis AI that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. The company intends to engage with OTC Markets at the earliest available opportunity to initiate that review process. Chief Executive Officer Naveen Kulkarni stated that the company takes this matter seriously and is committed to working constructively with OTC Markets to better understand the basis for the designation. The objective is to obtain clarity regarding the matter and take any appropriate steps necessary as the company moves through the review process.
The company remains committed to maintaining transparency with its shareholders and the broader investment community. Quantum Genesis AI intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available. For more information and updates, please visit https://www.qgaicorp.com and the company's profile at https://www.otcmarkets.com/stock/QGAI.
